A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy

点击翻译按钮获取中文摘要

Bone marrow transplantation can cure leukaemia but is often complicated by graft-versus-host disease (GVHD), which greatly reduces quality- of-life. A type of immune cell, called regulatory T cells (Tregs), may help. We will expand donor Tregs in the laboratory and infuse them into patients with chronic GVHD. We will gene-mark the cells so that we can understand what happens after infusion. We will also investigate whether interleukin-2 given at the same time can make the Tregs more effective.